F. Daschner, U. Frank, K. Huber
Oct 1, 1999
Citations
0
Influential Citations
0
Citations
Quality indicators
Journal
Drugs
Abstract
Grepafloxacin is a recently introduced extended spectrum fluoroquinolone, which retains the activity of older fluoroquinolones against Gram-negative organisms, while demonstrating enhanced activity against Gram-positive pathogens. In vitro studies have shown that grepafloxacin has superior activity compared with older quinolones against Streptococcus pneumoniae, irrespective of penicillin susceptibility, and enhanced efficacy compared with amoxicillin against Haemophilus influenzae and Moraxella catarrhalis, including β-lactamase–producing strains. In this study, the in vitro activity of grepafloxacin was compared with that of other oral antibiotics against 80 recent clinical isolates of typical pathogens causing community-acquired respiratory tract infections. The comparator antibioticswere clarithromycin, roxithromycin, azithromycin, ciprofloxacin, cefixime, amoxicillin, and amoxicillin-clavulanic acid. Activity was assessed by determining the MIC and MBC for each antibiotic.